AIM Expands Clinical Solutions Platform with Genetic Testing to Help Health Plans, ACOs, Providers Improve Quality, Decrease Costs
Solution to Ensure Appropriate Use of Testing and Counseling Supported Through New Partnership with InformedDNA
CHICAGO -- April 13, 2016 – AIM Specialty Health® (AIM), a national specialty benefits management leader, has announced the launch of its Genetic Testing Solution to meet growing demands, complexity, and financial implications of genetic testing.
In a new strategic partnership and equity investment with InformedDNA, the premier genetic testing clinical decision support and counseling services company, the AIM Genetic Testing Solution is available to payers and providers to help ensure appropriate, safe and affordable genetic testing and counseling for patients.
"Genetic testing and personalized medicine are powerful forces transforming healthcare as we know it. Through the integration of InformedDNA's comprehensive clinical evidence assessments and expert genetic counseling, we have expanded our platform to ensure appropriate use and patient value within this growing space,"
Given the rapid increase in new genetic tests offered, appropriate use and interpretation of genetic testing is a critical priority for health plans, providers, and members. Studies show that 30-50 percent of genetic tests may be inappropriately ordered and lead to unnecessary costs and poor patient care. The global market for genetic testing, forecast to reach $7.4 billion by 2020, is driven by the rising incidence of genetic diseases, growing awareness of the benefits of early diagnosis, and focus on personalized medicine. With a healthcare community focused on disease prediction, detection and prevention, health plans and other risk bearing entities need new approaches for promoting appropriate use and providing education.
The AIM Genetic Testing Solution expands on AIM's proven approach to ensuring appropriate and evidence-based care, along with increasing affordability and reducing costs. For more than 43 million health plan members, AIM operates programs for radiology, cardiology, oncology, specialty drugs, sleep medicine, musculoskeletal and pain management. In collaboration with InformedDNA, AIM now delivers a comprehensive solution that facilitates evidence-based genetic testing and genetic counseling. Leveraging the AIM technology platform, physicians are equipped with real-time genetic testing decision support, and health plan members benefit from convenient access to a nationwide network of board-certified genetics specialists.
"Genetic testing and personalized medicine are powerful forces transforming healthcare as we know it. Through the integration of InformedDNA's comprehensive clinical evidence assessments and expert genetic counseling, we have expanded our platform to ensure appropriate use and patient value within this growing space," said Brandon Cady, President and CEO of AIM. "Our Genetic Testing Solution also enhances AIM's award winning Medical Oncology Solution, giving providers and patients support through the entire continuum of cancer care – a compelling win for patients, providers, employers, and health plans."
"The pace of new genetic discoveries is staggering, making it impossible for most health plans and frontline physicians to stay current," said InformedDNA CEO David Nixon. "Providing physicians and patients evidence-based guidance in their decision making ensures high-quality care around genetic testing and the downstream healthcare informed by the test results. We are excited to be working with AIM to integrate our clinical expertise and capabilities within AIM's powerful services and technology platform. Our combined capabilities accelerate the rate at which our industry can eliminate inappropriate genetic testing while harnessing all the benefits personalized healthcare has to offer."
AIM Specialty Health®is focused on driving appropriate, safe and affordable care through the healthcare system. For more than 43 million members covered across 50 states, D.C. and US territories, AIM targets the quality and cost of clinical services including radiology, cardiology, oncology, specialty drugs, sleep medicine, musculoskeletal and pain management, and genetic testing. As a national leader in specialty benefits management, AIM helps health plans, providers and employers focus on the value of health decisions with an integrated suite of solutions combining clinical excellence, technology and superior customer service. AIM is a wholly owned subsidiary of Anthem, Inc. (ANTM) and a shareholder in InformedDNA. For more information, visit www.aimspecialtyhealth.com.
InformedDNA helps individuals and healthcare providers accurately interpret family health history and genetics, bringing the promise of personalized healthcare to life. InformedDNA is the authority on the appropriate use of genetic testing – leveraging the expertise of the largest network of independent board-certified genetics specialists to help ensure health plans, hospitals, employers, community clinicians and patients all have access to the highest quality genetic services. InformedDNA's key offerings include clinical genetic counseling, genetic testing utilization management, and personalized hereditary risk assessment and prevention solutions. For more information, visit www.InformedDNA.com.